Adjuvant activity of incomplete Freund's adjuvant (Q44199619)

30 November 2017

Adjuvant activity of incomplete Freund's adjuvant (English)

1 reference

30 November 2017

Jensen FC

1

1 reference

30 November 2017

Savary JR

series ordinal

2

1 reference

30 November 2017

Diveley JP

series ordinal

3

1 reference

30 November 2017

Chang JC

series ordinal

4

1 reference

30 November 2017

language of work or name

English

0 references

publication date

1 July 1998

1 reference

Advanced Drug Delivery Reviews

30 November 2017

1 reference

30 November 2017

32

1 reference

30 November 2017

3

1 reference

30 November 2017

173-186

1 reference

The effect of paraffin oil and mycobacteria on antibody formation and sensitization; a review

30 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900009-X

7 January 2021

Use of adjuvants in studies on influenza immunization. III. Degree of persistence of antibody in human subjects two years after vaccination

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900009-X

7 January 2021

The use of adjuvants in studies on influenza immunization. I. Measurements in monkeys of the dimensions of antigenicity of virus-mineral oil emulsions

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900009-X

7 January 2021

Direction of research on vaccination against influenza; new studies with immunologic adjuvants

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900009-X

7 January 2021

A serologic recapitulation of past experiences with influenza A; antibody response to monovalent vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900009-X

7 January 2021

Observations after human immunodeficiency virus immunization and challenge of human immunodeficiency virus seropositive and seronegative chimpanzees

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900009-X

7 January 2021

Prospects for the control of AIDS by immunizing seropositive individuals

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900009-X

7 January 2021

Effect of immunization with inactivated gp120-depleted human immunodeficiency virus type 1 (HIV-1) immunogen on HIV-1 immunity, viral DNA, and percentage of CD4 cells

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900009-X

7 January 2021

Results of a phase I clinical trial of a T-cell receptor peptide vaccine in patients with multiple sclerosis. I. Analysis of T-cell receptor utilization in CSF cell populations.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900009-X

7 January 2021

Results of a phase I clinical trial of a T-cell receptor vaccine in patients with multiple sclerosis. II. Comparative analysis of TCR utilization in CSF T-cell populations before and after vaccination with a TCRV beta 6 CDR2 peptide.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900009-X

7 January 2021

TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900009-X

7 January 2021

Allergen- and bacterial antigen-specific T-cell clones established from atopic donors show a different profile of cytokine production

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900009-X

7 January 2021

Establishment of stable, cell-mediated immunity that makes "susceptible" mice resistant to Leishmania major.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900009-X

7 January 2021

Molecular cloning of rat interleukin 4 cDNA and analysis of the cytokine repertoire of subsets of CD4+ T cells

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900009-X

7 January 2021

Adjuvants: current status, clinical perspectives and future prospects

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900009-X

7 January 2021

Peptide polymerisation facilitates incorporation into ISCOMs and increases antigen-specific IgG2a production

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900009-X

7 January 2021

Adjuvants--a classification and review of their modes of action

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900009-X

7 January 2021

Induction of CD8+ cytotoxic T cells by immunization with purified HIV-1 envelope protein in ISCOMs

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900009-X

7 January 2021

ISCOMs (immunostimulating complexes): the first decade

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900009-X

7 January 2021

Co-engagement of CD3 with LFA-1 or ICAM-1 adhesion molecules enhances the frequency of activation of single murine CD4+ and CD8+ T cells and induces synthesis of IL-3 and IFN-gamma but not IL-4 or IL-6.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900009-X

7 January 2021

The adjuvant effect of interleukin-12 in a vaccine against Leishmania major.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900009-X

7 January 2021

Administration of interleukin 12 in combination with type II collagen induces severe arthritis in DBA/1 mice

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900009-X

7 January 2021

Cloning, expression, and purification of rat IFN-gamma

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900009-X

7 January 2021

10.1016/S0169-409X(98)00009-X

Identifiers

DOI

1 reference

30 November 2017

1 reference